Immunotherapy for de novo renal transplantation: What's in the pipeline?

Drugs

Volumn 66, Issue 13, 2006, Pages 1665-1684

  Tedesco Silva Jr , Helio ^a   Machado, Paula Pinheiro ^a   Felipe, Claudia Rosso ^a   Pestana, Jose Osmar Medina ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ABE 071; AEB 071; ALEMTUZUMAB; ANISPERIMUS; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE 3 INHIBITOR; LF 15 0195; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; POLYCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TERIFLUNOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BRADYCARDIA; CHRONOTROPISM; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HUMAN; IMMUNOTHERAPY; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

POLYOMAVIRUS;

EID: 33748903363     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666130-00002     Document Type: Review

References (146)

1. Meier-Kriesche HU, Shold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 Mar; 4 (3): 378-83
2. Gloor J. Kidney transplantation in the hyperimmunized patient. Contrib Nephrol 2005; 146: 11-21
3. Young CJ, Gaston RS. African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes. Am J Med Sci 2002 Feb; 323 (2): 94-9
4. Peeters P, Terryn W, Vanholder R, et al. Delayed graft function in renal transplantation. Curr Opin Crit Care 2004 Dec; 10 (6): 489-98
5. Meyers CM, Kirk AD. Workshop on late renal allograft dys-function. Am J Transplant 2005 Jul; 5 (7): 1600-5
6. Kiberd BA. Cardiovascular risk reduction in renal transplantation: strategies for success. Minerva Urol Nefrol 2002 Jun; 54 (2): 51-63
7. Sia IG, Paya CV. Infectious complications following renal transplantation. Surg Clin North Am 1998 Feb; 78 (1): 95-112
8. Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004 Jun; 15 (6): 1582-8
9. Jindal RM, Joseph JT, Morris MC, et al. Noncompliance after kidney transplantation: a systematic review [published erratum appears in Transplant Proc 2004 Mar; 36 (2): 409]. Transplant Proc 2003 Dec; 35 (8): 2868-72
10. Butler JA, Roderick P, Mulle M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004 Mar 15; 77 (5): 769-76
11. First MR, Fitzsimmons WE. New drugs to improve transplant outcomes. Transplantation 2004 May 15; 77 (9 Suppl.): S88-92
12. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J 2004 Dec 31; 45 (6): 1127-31
13. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37 (2): 1211-3
14. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37 (2): 867-70
15. Silva Jr HT, for the Modified Release De Novo Kidney Study Group. A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and Neoral® (cyclosporine)/MMF in de novo kidney transplant recipients: 12-month results [abstract no. 748]. Am J Transplant 2006; Suppl.: 318
16. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-52
17. Ingelfinger JR, Schawartz RS. Immunosuppression-the promise of specificity. N Engl J Med 2005 Aug 25; 353 (8): 836-9
18. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991 Sep 1; 174 (3): 561-9
19. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997 Dec 1; 159 (11): 5187-91
20. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 Nov 13; 349 (20): 1907-15
21. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005 Mar; 5 (3): 443-53
22. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005 Sep 15; 80 (5): 555-63
23. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997 Aug 5; 94 (16): 8789-94
24. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002 Jun; 46 (6): 1470-9
25. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 Aug 25; 353 (8): 770-81
26. Griyno AJ, Halloran P, Vanrenterghem Y, et al. Belatacept (LEA29Y) as part of a CNI-FREE regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss [abstract no. 946]. Am J Transplant 2005; 5 Suppl. 11: 397
27. Belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial: extended criteria donors (BEN-EFIT-EXT) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 16]
28. Säemann MD, Zeyda M, Stulnig TM, et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 2004 Oct; 17 (9): 481-9. Epub 2004 Sep 11
29. Behbod F, Nagy ZS, Stepkowski SM, et al. Specific inhibition of Stat5a/b promotes apoptosis of IL-2R-responsive primary and tumor-derived lymphoid cells. J Immunol 2003; 171: 3919-27
30. Tomita K, Saijo K, Yamasaki S, et al. Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex. J Biol Chem 2001 Jul 6; 276 (27): 25378-85
31. Säemann MD, Zeyda M, Diakos C, et al. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003 Jun 15; 75 (11): 1864-72
32. Li XC, Ima A, Li Y, et al. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 2000 Feb 1; 164 (3): 1193-9
33. Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002 Jan 15; 99 (2): 680-9
34. Behbod F, Erwin-Cohen RA, Wang ME, et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 2001 Mar 15; 166 (6): 3724-32
35. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003 Oct 31; 302 (5646): 875-8
36. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004 Jan; 4 (1): 51-7
37. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005 Apr 15; 79 (7): 791-801
38. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004 Dec; 8 (6): 613-29
39. Stepkowski SM, Kao J, Wang ME, et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005 Oct 1; 175 (7): 4236-46
40. Chan G, Wang C, Boy M, et al. Dose-dependent reduction in psoriasis severity as evidence of immunosuppressive activity of an oral Jak3 inhibitor in humans [abstract no. 60]. Am J Transplant 2006; 6 Suppl. 2: 87
41. Weimar W, Gaston R, Brennan D, et al. A3921007 Study Group. Phase I evaluation of the safety of a JAK3 inhibitor, Cp-690,550 in stable kidney transplant recipients [abstract no. 58]. Am J Transplant 2006; 6 Suppl. 2: 86
42. Weimar W, Duplin M, Gaston R, et al. A3921007 Study Group. Multiple dose pharmacokinetics of Cp-690,550 in stable renal allograft recipients dosed with Cp-690,550 in combination with other immunosuppressive agents [abstract no. 2549]. American J Transplant 2006; 6 Suppl. 2: 900
43. Baan CC, Schoordijk-Verschoor W, Korevaar SS, et al. Changes in peripheral blood lymphocyte subsets, IFN-γ production capacity and gene expression following treatment with the JAK-3 inhibitor Cp-690,550 in stable renal allograft recipients [abstract no. 59]. Am J Transplant 2006; 6 Suppl. 2: 86
44. A 6-month, phase 2, multicenter, randomized, open-label, comparative study of 2 dose levels of Cp-690,550 administered concomitantly with IL-2 receptor antagonist induction therapy, mycophenolate mofetil and corticosteroids versus a tacrolimus-based immunosuppressive regimen for the prevention of allograft rejection in de novo renal allograft recipients [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 16]
45. Silva HT, Morris RE. Leflunomide and malononitriloamides. Expert Opin Investig Drugs 1997 Jan; 6 (1): 51-64
46. Gregory CR, Silva HT, Patz JD, et al. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant Proc 1998 Jun; 30 (4): 1047-8
47. Jin MB, Nakayama M, Ogata T, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery 2002 Jul; 132 (1): 72-9
48. Fitzsimmons WE, First MR. FK778, a synthetic malononitrilamide. Yonsei Med J 2004 Dec 31; 45 (6): 1132-5
49. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997 Jul 1; 159 (1): 22-7
50. Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998 Dec 1; 336 (Pt 2): 299-303
51. Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998 Feb 15; 160 (4): 1581-8
52. Slauson SD, Silva HT, Sherwood SW, et al. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett 1999; 67: 179-83
53. Zeyda M, Geyeregger R, Poglitsch M, et al. The novel immunosuppressant FK778 inhibits formation of the immunologic Synapse. Transplant Proc 2005 May; 37 (4): 1970-1
54. Zeyda M, Stuhlmeier KM, Kirsch B, et al. The malononitrilamide FK778 inhibits activation of NF-kappaB in human dendritic cells. Transplant Proc 2005 May; 37 (4): 1968-9
55. Deuse T, Schrepfer S, Schafer H, et al. FK778 attenuates lymphocyte-endothelium interaction after cardiac transplantation: in vivo and in vitro studies. Transplantation 2004 Jul 15; 78 (1): 71-7
56. Schrepfer S, Deuse T, Schafer H, et al. FK778, a novel immunosuppressive agent, reduces early adhesion molecule upregulation and prolongs cardiac allograft survival. Transpl Int 2005 Feb; 18 (2): 215-20
57. Crews GM, Erickson L, Pan F, et al. Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats. Transplant Proc 2005 May; 37 (4): 1926-8
58. Bilolo KK, Ouyang J, Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003 Jun 15; 75 (11): 1881-7
59. Vu MD, Qi S, Wang X, et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. Transplantation 2003 May 15; 75 (9): 1455-9
60. Zeng H, Waldman WJ, Yin DP, et al. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 2005 Jan 15; 79 (1): 17-22
61. Yamamoto S, Okuda T, Yamasaki K, et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. Transplant Proc 2005 Jan-Feb; 37 (1): 126-9
62. Yamamoto S, Okuda T, Yamasaki K, et al. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. Transplantation 2004 Dec 15; 78 (11): 1618-25
63. Kyles AE, Gregory CR, Griffey SM, et al. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation 2003 Apr 27; 75 (8): 1128-33
64. Alessiani M, Zonta S, Abbiati F, et al. Efficacy of Malononitrilamide FK778 in a preclinical model of small bowel transplantation. Transplant Proc 2005 Jul-Aug; 37 (6): 2719-21
65. Qi S, Zhu S, Xu D, et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. Transplantation 2003 Apr 27; 75 (8): 1124-8
66. Deuse T, Schrepfer S, Reichenspurner H. Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation 2003 Dec 15; 76 (11): 1627-9
67. Deuse T, Schrepfer S, Reichenspurner H. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. Transplantation 2004 Feb 27; 77 (4): 509-13
68. Pan F, Ebbs A, Wynn C, et al. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation 2003 Apr 27; 75 (8): 1110-4
69. Savikko J, Von Willebrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003 Aug 15; 76 (3): 455-8
70. Hardinger KL, Wang CD, Schnitzler MA, et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2002 Oct; 2 (9): 867-71
71. Knight DA, Hejmanowski AQ, Dierksheide JE, et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001 Jan 15; 71 (1): 170-4
72. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999 Sep 27; 68 (6): 814-25
73. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004 May 15; 77 (9): 1460-1
74. Evers DL, Wang X, Huong SM, et al. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 2005 Jan; 65 (1): 1-12
75. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005 Mar 17; 352 (11): 1157-8
76. Farasati NA, Shapiro R, Vats A, et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005 Jan 15; 79 (1): 116-8
77. Molinaro M, Carazzone C, Barbano D, et al. Assessment of an LC-MS method for plasma quantification of the new immunosuppressant FK778 through comparison with HPLC-UV. Transplant Proc 2005 Jul-Aug; 37 (6): 2722-7
78. Birsan T, Dambrin C, Klupp J, et al. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 2003 Apr-Jun; 11 (2): 163-7
79. Birsan T, Dambrin C, Klupp J, et al. In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates. Transpl Int 2003 May; 16 (5): 354-60
80. Vanrenterghem Y, Van Hooff JP, Klinger M, et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 2004 Jul 15; 78 (1): 9-14
81. Fawcett J, Johnson DW. FK778: a powerful immunosuppressive, but will it really be good for you? Transplantation 2004 Jul 15; 78 (1): 7-8
82. Study of FK778 in renal transplantation recipients with untreated BK nephropathy. Clinical trials 2005 Aug [online]. Available from URL: http://www.clinicaltrials.gov /ct/show/nct [Accessed 2006 Aug 16]
83. Silva HT, Felipe CR, Pestana JOM. FTY720. Curr Opin Organ Transplant 2002; 7: 342-52
84. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-59
85. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004 Jul; 4 (7): 1019-25
86. Honing SM, Fu S, Mao X, et al. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 2003 Mar; 111 (5): 627-37
87. Yopp AC, Fu S, Honing SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004 Jul 15; 173 (2): 855-65
88. Bohler T, Budde K, Neumayer HH, et al. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005 Feb 27; 79 (4): 492-5
89. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000 Jun 1; 164 (11): 5761-70
90. Dragun D, Böhler T, Nieminen-Kelhä N, et al. FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int 2004 Mar; 65 (3): 1076-83
91. Kovarik JM, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004 May; 57 (5): 586-91
92. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004 May; 44 (5): 532-7
93. Kovarik JM, Slade A, Riviere GJ, et al. Pharmacokinetics are predictable and linear over an extended exposure range [abstract no. 266]. Am J Transplant 2004; 4 Suppl. 8: 231
94. Kovarik JM, Schmouder R, Barilla D, et al. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Ann Pharmacother 2004 Jul-Aug; 38 (7-8): 1153-8. Epub 2004 May 11
95. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002 Apr; 13 (4): 1073-83
96. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003 Oct 15; 76 (7): 1079-84
97. Skerjanec A, Tedesco H, Neumayer HH, et al. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol 2005 Nov; 45 (11): 1268-78
98. Kovarik JM, Slade A, Sugita Y, et al. FTY720 pharmacokinetics are similar across ethnic-racial groups [abstract no. 264]. Am J Transplant 2004; 4 Suppl. 8: 230
99. Kovarik JM, Schmouder RL, Serra D, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 2005 Apr; 45 (4): 446-52
100. Budde K, Schmouder R, Nashan B, et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 2003 Jul; 3 (7): 846-54
101. Bohler T, Waiser J, Schutz M, et al. Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. Int J Clin Pharmacol Ther 2003 Oct; 41 (10): 482-7
102. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004 Dec; 26 (6): 585-7
103. Park SI, Felipe CR, Machado PG, et al. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. Braz J Med Biol Res 2005 May; 38 (5): 683-94
104. Slade A, Kovarik JM, Hunt TL, et al. FTY720 high dose: Lymphocyte response at single doses up to 40mg [abstract no. 293]. Am J Transplant 2004; 4 Suppl. 8: 238
105. Kovarik JM, Schmidli H, Men G, et al. Insights into FTY720 use in transplantation from human exposure-lymphocyte mechanistic model based on clinical data [abstract no. 134]. Am J Transplant 2005; 5 Suppl. 11: 190
106. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005 Jun 15; 79 (11): 1553-60
107. Lorber M, Kahan B, Tedesco-Silva H, et al. FTY720 in combination with everolimus: a novel CNI-free regimen effective in patients at high risk for DGF [abstract no. 1572]. Am J Transplant 2003; 5 Suppl. 3: 555
108. Mulgaonkar S, Tedesco H, Oppenheimer F, et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant. 2006; 6: 1848-1857
109. Calne SR. FYT: not just a homely drug. Transplantation 2004 May 15; 77 (9): 1327
110. Mark Pescovitz, the FTY720 0125 Study Group. A one year randomized controlled efficacy and safety trial of FTY720, versus mycophenolate mofetil with cyclosporine and corticosteroids in de novo renal transplantation [abstract no. 52]. American J Transplant 2006; Suppl.: 84
111. Salvadori M, Budde K, Charpentier B, et al. FTY720 a novel immunomodulator, vs. mycophenolate mofetil with cyclosporine micro-emulsion in de novo renal transplantation, a one-year randomized controlled trial in 668 patients from Europe and Australia [abstract no. 829.]. Am J Transplant 2006; Suppl.: 346
112. Tedesco H, Szakaly P, Shoker A, et al. FTY720 vs. MMF in de novo renal transplant patients on full-dose neoral: 6-month results of a double-blind study [abstract no. 51]. Am J Transplant 2006; Suppl.: 83
113. Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004 Jul; 20 (1): 16-24
114. Amemiya H. 15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. Artif Organs 1996 Aug; 20 (8): 832-5
115. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 Jun; 4 (6): 996-1001
116. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002 Nov; 2 (10): 898-903
117. Vicenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 2003 Mar; 55 (1): 57-66
118. Kalunian KC, Davis Jr JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46 (12): 3251-8
119. Dumont FJ. IDEC-131: IDEC/Eisai. Curr Opin Investig Drugs 2002; 3 (5): 725-34
120. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004; 103 (4): 1229-36
121. Norman DJ, Vincenti F, de Mattos AM, et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70 (12): 1707-12
122. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11 (6): 465-71
123. Yang H, Chen G, Kanai N, et al. Monotherapy with LF 15-0195, an analogue of 15-deoxyspergualin, significantly prolongs renal allograft survival in monkeys. Transplantation 2003 Apr 27; 75 (8): 1166-71
124. Min WP, Zhou D, Ichim TE, et al. Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation 2003 Apr 27; 75 (8): 1160-5
125. Luke PP, Deng JP, Lian D, et al. Prolongation of allograft survival by administration of anti-CD45RB monoclonal antibody is due to alteration of CD45RB: CD45RB T-cell proportions. Am J Transplant. Epub 2006 Jul 6
126. Zhong T, Liu Y, Jiang J, et al. Long-term limb allograft survival using a short course of anti-C45RB monoclonal antibody, LF15-0195 and rapamycin in a mouse model [abstract no. 969]. American J Transplant 2006; 6 Suppl. 2: 393
127. Tan S-L, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signaling. Biochem J 2003; 376: 545-52
128. Slade, AV, Agyemang A, Sieberling M, et al. NVP-AEB071: human pharmacodynamics in combination with mycophenolic acid [abstract no. 396]. Am J Transplantation 2006; 6 Suppl. 2: 99
129. Slade A, Hijazi Y, Wagner J, et al. NVP-AEB071: pharmacokinetics and pharmacodynamic activity of a novel T-cell activation inhibitor under multiple-dose conditions [abstract no. 392]. American J Transplant 2006; 6 Suppl. 2: 198
130. Slade A, Bartlett M, van Marle S, et al. NVP-AEB071 pharmacokinetics: combination with everolimus does not result in clinically relevant interaction [abstract no. 2435]. Am J Transplant 2006; 6 Suppl. 2: 865
131. Slade A, Pfrunder A, Koelle EU, et al. NVP-AEB071 pharmacokinetics: combination with mycophenolate mofetil (Cellcept®) is safe and does not result in an interaction [abstract no. 2436]. Am J Transplant 2006; 6 Suppl. 2: 866
132. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients [plubished erratum appears in Lancet 1998 Aug 1; 352 (9125): 408]. Lancet 1998; 351 (9117): 1701-2
133. ClinicalTrials.gov. A service of the US National Institutes of Health developed by the National Library of Medicine [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 16 Aug]
134. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76 (1): 120-9
135. Silveira FP, Marcos A, Kwak EJ, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect. Epub 2006 Jan 2
136. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5 (3): 465-74
137. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136 (4): 754-60
138. Zhang PL, Malek SK, Prichard JW, et al. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without campath-1H (alemtuzumab) induction therapy. Am J Transplant 2005; 5 (3): 604-7
139. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5 (6): 1347-53
140. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80 (8): 1051-9
141. Knechtle SJ, Pirsch JD, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3 (6): 722-30
142. Vatshala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005 Sep 27; 80 (6): 765-74
143. Tan HP, Kaczorowski D, Basu A, et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37 (10): 4235-40
144. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005 Apr; 200 (4): 505-15
145. Hariharan S, Kasiske B, Matas A, et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004 Jul; 4 (7): 1179-83
146. Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005 Mar; 6 (2): 163-8